{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:37:03Z","timestamp":1778837823965,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.leukres.2018.02.014","type":"journal-article","created":{"date-parts":[[2018,2,24]],"date-time":"2018-02-24T17:45:02Z","timestamp":1519494302000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Enhanced perforin expression associated with dasatinib therapy in natural killer cells"],"prefix":"10.1016","volume":"68","author":[{"given":"Noriyoshi","family":"Iriyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihito","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2018.02.014_bib0005","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.02.014_bib0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","article-title":"Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia","volume":"94","author":"Kim","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.02.014_bib0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12185-013-1483-9","article-title":"Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia","volume":"99","author":"Kumagai","year":"2014","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2018.02.014_bib0020","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/leu.2012.348","article-title":"Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy","volume":"27","author":"Mustjoki","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.02.014_bib0025","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24096","article-title":"Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2018.02.014_bib0030","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/cncr.29933","article-title":"Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: effects on response and toxicity","volume":"122","author":"Schiffer","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2018.02.014_bib0035","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1002\/cam4.925","article-title":"Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes","volume":"5","author":"Iriyama","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.leukres.2018.02.014_bib0040","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1\u2009year (DADI trial): a multicentre phase trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2018.02.014_bib0045","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.02.014_bib0050","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.02.014_bib0055","doi-asserted-by":"crossref","first-page":"e28925","DOI":"10.4161\/onci.28925","article-title":"Dasatinib promotes Th1-type responses in granzyme B expressing T-cells","volume":"3","author":"Kreutzman","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.leukres.2018.02.014_bib0060","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.exphem.2010.09.005","article-title":"Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy","volume":"39","author":"Jalkanen","year":"2011","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.leukres.2018.02.014_bib0065","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/978-1-61737-950-5_9","article-title":"Phospho flow cytometry methods for the analysis of kinase signaling in cell lines and primary human blood samples","volume":"699","author":"Krutzik","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.leukres.2018.02.014_bib0070","doi-asserted-by":"crossref","first-page":"e113722","DOI":"10.1371\/journal.pone.0113722","article-title":"Induced differentiation of human myeloid leukemia cells into M2 macrophages by combined treatment with retinoic acid and 1\u03b1,25-dihydroxyvitamin D3","volume":"9","author":"Takahashi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2018.02.014_bib0075","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/hon.2034","article-title":"Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in vitro study","volume":"31","author":"Uchiyama","year":"2013","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.leukres.2018.02.014_bib0080","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/leu.2011.135","article-title":"Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation","volume":"25","author":"Kreutzman","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.02.014_bib0085","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.critrevonc.2013.10.005","article-title":"Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?","volume":"89","author":"Paydas","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.leukres.2018.02.014_bib0090","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4161\/cbt.27310","article-title":"Large granular lymphocytosis during dasatinib therapy","volume":"15","author":"Qiu","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.leukres.2018.02.014_bib0095","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","article-title":"Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy","volume":"85","author":"Rohon","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2018.02.014_bib0100","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","article-title":"Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy","volume":"116","author":"Kreutzman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.014_bib0105","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.4049\/jimmunol.162.5.2785","article-title":"Role of a STAT binding site in the regulation of the human perforin promoter","volume":"162","author":"Yu","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2018.02.014_bib0110","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1046\/j.1365-2141.2001.02995.x","article-title":"Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells","volume":"114","author":"Lehmann","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2018.02.014_bib0115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0923-2494(90)90017-S","article-title":"Involvement of granzyme B and perforin gene expression in the lytic potential of human natural killer cells","volume":"141","author":"Cl\u00e9ment","year":"1990","journal-title":"Res. Immunol."},{"key":"10.1016\/j.leukres.2018.02.014_bib0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13684730210002319","article-title":"Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia","volume":"7","author":"Aswald","year":"2002","journal-title":"Cytokines Cell. Mol. Ther."},{"key":"10.1016\/j.leukres.2018.02.014_bib0125","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1038\/sj.leu.2403933","article-title":"Imatinib mesylate suppresses cytokine synthesis by activated CD4\u2009T cells of patients with chronic myelogenous leukemia","volume":"19","author":"Gao","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.02.014_bib0130","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.02.014_bib0135","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.23923","article-title":"Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2018.02.014_bib0140","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/leu.2016.121","article-title":"Safety and efficacy of the combination of pegylated interferon-\u03b12b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients","volume":"30","author":"Hjorth-Hansen","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2018.02.014_bib0145","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s12185-009-0327-0","article-title":"A Phase I\/II study of nilotinib in Japanese patients with imatinib-resistant or \u2013intolerant Ph+ CML or relapsed\/refractory Ph+ ALL","volume":"89","author":"Tojo","year":"2009","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2018.02.014_bib0150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00228-015-1968-y","article-title":"Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia","volume":"72","author":"Ishida","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.leukres.2018.02.014_bib0155","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2018.02.014_bib0160","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia","volume":"36","author":"Hu","year":"2004","journal-title":"Nat. Genet."},{"key":"10.1016\/j.leukres.2018.02.014_bib0165","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1002\/cncr.30197","article-title":"A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase","volume":"122","author":"Takahashi","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2018.02.014_bib0170","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1016\/S2352-3026(15)00021-6","article-title":"Long-term molecular and cytogenetic response and survival outcomes with imatinib 400\u2009mg, imatinib 800\u2009mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials","volume":"2","author":"Jain","year":"2015","journal-title":"Lancet Haematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618300493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618300493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T08:29:01Z","timestamp":1693556941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618300493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":34,"alternative-id":["S0145212618300493"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.02.014","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced perforin expression associated with dasatinib therapy in natural killer cells","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}